Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
Current regulatory and compounding status of PT-141 (bremelanotide), including FDA approval history, Vyleesi labeling, 503A/503B compounding rules, and post-market safety data.
Read clinical reviewA detailed review of bremelanotide (Vyleesi) FDA adverse event reports, FAERS safety signals, labeling updates, and post-market surveillance findings for clinicians and patients.
Read clinical reviewA complete regulatory history of bremelanotide (Vyleesi), including FDA approval date, label requirements, RECONNECT trial data, REMS status, and post-market safety updates.
Read clinical reviewA complete review of bremelanotide (Vyleesi) regulatory approvals, FDA labeling, global scheduling, and post-market safety data for hypoactive sexual desire disorder in premenopausal women.
Read clinical reviewA comprehensive review of FDA label changes for PT-141 (bremelanotide, Vyleesi) from initial approval through 2026, including safety updates, boxed warning revisions, and post-market surveillance findings.
Read clinical reviewA clinical deep-dive into bremelanotide's regulatory history, prescribing label, post-market safety data, and what the next generation of melanocortin-based therapies may look like.
Read clinical reviewA clinical review of bremelanotide (Vyleesi/PT-141) legal history, patent disputes, FDA regulatory pathway, label requirements, and ongoing post-market safety obligations.
Read clinical review